Investors Encouraged to Reach Out Ahead of Deadline for Rocket Pharmaceuticals Lawsuit

Attention Rocket Pharmaceuticals investors! If you have suffered financial losses as a result of investing in Rocket Pharmaceuticals (NASDAQ: RCKT), a major deadline is approaching. Berger Montague PC, a respected law firm based in Philadelphia, is currently handling a class action lawsuit aimed at securing justice for affected investors. Those who purchased Rocket Pharmaceuticals shares between September 17, 2024, and May 26, 2025, are urged to contact the firm before August 11, 2025, to understand their rights and potential for compensation.

Background on the Lawsuit

The lawsuit stems from allegations that Rocket Pharmaceuticals failed to disclose important safety information about its clinical trials, specifically concerning the RP-A501 program. Key details regarding the use of an immunomodulatory agent were allegedly omitted, leading to significant consequences for investors following the revelation of these issues. The situation escalated dramatically when news broke of a patient death linked to the trial, leading to a series of events that resulted in a steep decline in share prices. On May 28, 2025, after the company confirmed the clinical hold and the unfortunate patient outcome, Rocket Pharmaceuticals' stock plummeted from $6.27 to $2.33, causing immense losses for shareholders.

About Rocket Pharmaceuticals

Headquartered in Cranbury, New Jersey, Rocket Pharmaceuticals focuses on developing gene therapies aimed at treating rare and life-threatening diseases. The company's innovative approach has garnered attention, but recent developments challenge both its credibility and its market position. The ongoing lawsuit seeks to hold the company accountable for the alleged misstatements and omissions, ensuring that investors are adequately informed and compensated.

Berger Montague's Role

Founded in 1970, Berger Montague has established a strong reputation as a leading advocate for investors in securities class action lawsuits. With offices across major cities including Philadelphia, Minneapolis, and San Francisco, the firm offers a wealth of experience representing individual and institutional investors. They have earned recognition for their commitment to fighting for justice and recovering funds for those affected by corporate malfeasance.

How to Get Involved

As the deadline approaches, it is crucial for potential plaintiffs to act swiftly. Interested investors who believe they have been negatively impacted by their investment in Rocket Pharmaceuticals are encouraged to reach out to Berger Montague. Understanding your rights and options could provide the clarity you need during this tumultuous time. For those looking to get in touch, here are the contact details:

- Andrew Abramowitz, Senior Counsel: (215) 875-3015, [email protected]
- Caitlin Adorni: (267) 764-4865, [email protected]

Remember, August 11, 2025, is the deadline for seeking lead plaintiff status. It's a vital opportunity to stand up for your rights as an investor.

Conclusion

In conclusion, the situation surrounding Rocket Pharmaceuticals serves as a reminder of the inherent risks involved in investment, particularly in the biotech sector. As events unfold, the firm of Berger Montague invites affected investors to engage in this critical legal action to pursue potential recovery. If you are one of those impacted, don’t miss this chance to explore your options and take the necessary steps toward justice.